Valeant appoints Humphries executive VP, dermatology

Valeant Pharmaceuticals International announced that it has appointed William D. Humphries as executive vice president, dermatology, effective Jan. 2.

Humphries has almost 30 years of experience in the dermatology and specialty pharmaceuticals industry, and most recently served as CEO of the North America business of Merz GmbH & Co. KGaA. He also served as president of Stiefel, a subsidiary of GlaxoSmithKline, and held multiple senior roles at Allergan, according to a press release.

Humpries will be part of Valeant’s executive committee and will report directly to Joseph C. Papa, Valeant’s chairman and CEO.

“Bill has an unparalleled understanding of the dermatology and the aesthetics space and a proven track record of successfully developing and commercializing products in these therapeutic areas,” Papa stated in the release. “We look forward to his contributions as we continue working toward a recovery of our core prescription dermatology business.”

Valeant also announced that Anne Whitaker, executive vice president and company group chairman, will leave the company of Jan. 13. Rob Rosiello, who previously served as Valeant chief financial officer from July 2015 through Aug 2016, and Ari Kellen, MBBCh, MBA, executive vice president and company group chairman, will leave the company on Dec. 31, according to the release.

Reference: www.valeant.com